- Home
- NDMO vs LXRX Comparison
NDMO vs LXRX Comparison
Compare NDMO & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDMO
- LXRX
- Stock Information
- Founded
- NDMO 2019
- LXRX 1995
- Country
- NDMO United States
- LXRX United States
- Employees
- NDMO N/A
- LXRX N/A
- Industry
- NDMO Trusts Except Educational Religious and Charitable
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- NDMO Finance
- LXRX Health Care
- Exchange
- NDMO Nasdaq
- LXRX Nasdaq
- Market Cap
- NDMO 633.1M
- LXRX 552.4M
- IPO Year
- NDMO N/A
- LXRX 2000
- Fundamental
- Price
- NDMO $10.61
- LXRX $1.46
- Analyst Decision
- NDMO
- LXRX Buy
- Analyst Count
- NDMO 0
- LXRX 5
- Target Price
- NDMO N/A
- LXRX $3.23
- AVG Volume (30 Days)
- NDMO 218.6K
- LXRX 2.2M
- Earning Date
- NDMO 01-01-0001
- LXRX 11-06-2025
- Dividend Yield
- NDMO 6.75%
- LXRX N/A
- EPS Growth
- NDMO N/A
- LXRX N/A
- EPS
- NDMO N/A
- LXRX N/A
- Revenue
- NDMO N/A
- LXRX $70,864,000.00
- Revenue This Year
- NDMO N/A
- LXRX $66.55
- Revenue Next Year
- NDMO N/A
- LXRX N/A
- P/E Ratio
- NDMO N/A
- LXRX N/A
- Revenue Growth
- NDMO N/A
- LXRX 1255.21
- 52 Week Low
- NDMO $8.99
- LXRX $0.28
- 52 Week High
- NDMO $11.24
- LXRX $1.66
- Technical
- Relative Strength Index (RSI)
- NDMO 52.85
- LXRX 53.11
- Support Level
- NDMO $10.48
- LXRX $1.18
- Resistance Level
- NDMO $10.82
- LXRX $1.64
- Average True Range (ATR)
- NDMO 0.13
- LXRX 0.12
- MACD
- NDMO -0.00
- LXRX 0.01
- Stochastic Oscillator
- NDMO 38.24
- LXRX 59.78
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.